Massimo Squatrito
YOU?
Author Swipe
BIOM-05 CHARACTERIZATION OF TUMOR-DERIVED DNA MUTATIONS, COPY NUMBER CHANGES, AND METHYLATED FRAGMENTS WITHIN CEREBROSPINAL FLUID AND PLASMA FROM PATIENTS UNDERGOING SURGERY FOR LUNG CANCER BRAIN METASTASIS Open
Surgical management of brain metastasis (BrM) improves outcomes in selected patients, yet predicting CNS progression following surgery remains challenging. To identify circulating tumor-(ct)DNA markers associated with disease progression, …
View article: supplementary materials 1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
supplementary materials 1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
supplementary materials
View article: Figure S2 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S2 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Additional RNA sequencing analysis performed from CANCAP03 study.
View article: Data from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Data from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Purpose:The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombinati…
View article: Figure S3 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S3 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Single cell RNA Seq data
View article: Figure S1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Figure S1 from Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Graph of % change in PARylated protein (PAR) expression against % change in PSA from baseline (pre-treatment) for olaparib and olaparib plus degarelix cohorts.
View article: Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer Open
Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombinat…
A new effLuc/Kate dual reporter allele for tumor imaging in mice Open
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases, such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-env…
TMIC-60. CROSS-SPECIES ANALYSIS OF HUMAN AND NEW MOUSE MODELS OF GBM SUBTYPES IDENTIFIES VISTA AS A PROMISING IMMUNOTHERAPY TARGET Open
Immunotherapy is a promising treatment modality for GBM; however, clinical trials thus far have failed to provide significant clinical benefit to most patients. GBM is one of the “immune cold” tumors characterized by poor infiltration of T…
View article: Table S3 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S3 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results T98G TMZ
View article: Table S2 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Table S2 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Table S2. Phenotypic CRISPR-screen data analysis
View article: Table S1 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Table S1 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Table S1. GBM-sLCR features
View article: Table S1 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S1 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
shRNA library
View article: Table S5 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S5 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results T98G Val-083
View article: Table S2 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S2 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results U251 TMZ
View article: Table S2 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S2 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results U251 TMZ
View article: Table S1 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Table S1 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Table S1. GBM-sLCR features
View article: Table S3 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Table S3 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Table S3. List of reagents, software and deposited data
View article: Supplementary Figures from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Supplementary Figures from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Combined supplementary Figures
View article: Data from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Data from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Glioblastoma (GBM) is the most frequent and aggressive primary tumor type in the central nervous system in adults. Resistance to chemotherapy remains one of the major obstacles in GBM treatment. Identifying and overcoming the mechanisms of…
View article: Table S4 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S4 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results U251 Val-083
View article: Supplementary Figures from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Supplementary Figures from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Combined supplementary Figures
View article: Supplementary Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Supplementary Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Figures, legends and References
View article: Table S3 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S3 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results T98G TMZ
View article: Table S4 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S4 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Screening results U251 Val-083
View article: Data from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Data from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
Glioblastoma (GBM) is the most frequent and aggressive primary tumor type in the central nervous system in adults. Resistance to chemotherapy remains one of the major obstacles in GBM treatment. Identifying and overcoming the mechanisms of…
View article: Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Glioblastoma is a lethal brain tumor that exhibits heterogeneity and resistance to therapy. Our understanding of tumor homeostasis is limited by a lack of genetic tools to selectively identify tumor states and fate transitions. Here, we us…
View article: Table S1 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Table S1 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma Open
shRNA library
View article: Table S3 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Table S3 from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Table S3. List of reagents, software and deposited data
View article: Supplementary Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing
Supplementary Data from Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing Open
Supplementary Figures, legends and References